Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 18, 2018 - Issue 6
Submit an article Journal homepage
3,985
Views
15
CrossRef citations to date
0
Altmetric
Original Research

Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis

Ana-Maria IonescuJohnson & Johnson Global Public Health, New Brunswick, NJ, USACorrespondence[email protected]
View further author information
,
Abela Mpobela AgnarsonJohnson & Johnson Global Public Health, New Brunswick, NJ, USAView further author information
,
Chrispin KambiliJohnson & Johnson Global Public Health, South Raritan, NJ, USAView further author information
,
Laurent MetzJohnson & Johnson Global Public Health, Asia Pacific, SingaporeView further author information
,
Jonathan KfouryL.E.K. Consulting, San Francisco, CA, USAView further author information
,
Steven WangL.E.K. Consulting, Boston, MA, USAView further author information
,
Abeda WilliamsPharmaceutical Division of Johnson and Johnson, Janssen Pharmaceutica South Africa, Johannesburg, South AfricaView further author information
,
Vikram SinghJanssen India, Pharmaceutical Division of Johnson and Johnson Pvt. Ltd., IndiaView further author information
&
Adrian ThomasJohnson & Johnson Global Public Health, New Brunswick, NJ, USAView further author information
 show all
Pages 677-689 | Received 09 Jul 2018, Accepted 30 Jul 2018, Published online: 23 Aug 2018

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Abela Mpobela Agnarson, Abeda Williams, Chrispin Kambili, Gunnar Mattson & Laurent Metz. (2020) The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa. Expert Review of Anti-infective Therapy 18:5, pages 475-483.
Read now

Articles from other publishers (14)

Pugazhenthan Thangaraju, Hemasri Velmurugan & Sree Sudha Tanguturi Yella. (2024) Bedaquiline’s Safety Profile Monitoring in India: Considerations for Future - A Systematic Review. Current Drug Safety 19:1, pages 24-32.
Crossref
N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova & N. P. Doktorova. (2023) Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 16:2, pages 162-175.
Crossref
Kosuke Jo, Masahiro Kawashima, Junko Suzuki, Yoshiteru Morio & Hideaki Nagai. (2023) The Treatment and Prognosis of Older Tuberculosis Patients with a Poor Performance Status Caused by Underlying Diseases. Internal Medicine 62:12, pages 1743-1748.
Crossref
Hae-Young Park, Jin-Won Kwon, Hye-Lin Kim, Sun-Hong Kwon, Jin Hyun Nam, Serim Min, In-Sun Oh, Sungho Bea & Sun Ha Choi. (2023) Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens. Journal of Korean Medical Science 38:21.
Crossref
Aastha Gupta, Sandeep Juneja, Suvanand Sahu, Mohammed Yassin, Grania Brigden, Eliud Wandwalo, Saurabh Rane, Fuad Mirzayev & Matteo Zignol. (2022) Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis. PLOS Global Public Health 2:11, pages e0001287.
Crossref
А. V. Kukurika. (2022) Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15:3, pages 353-362.
Crossref
Max R. O'Donnell, Nesri Padayatchi, Allison Wolf, Jennifer Zelnick, Amrita Daftary, Catherine Orrell, Camus Nimmo, Matthew Baldwin, Resha Boodhram, Bhavna Maharaj, K. Rivet Amico, Kogieleum Naidoo & Gerald Friedland. (2022) Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal of Acquired Immune Deficiency Syndromes 90:3, pages 325-332.
Crossref
Gabriela Beatriz Gomez, Mariana Siapka, Francesca Conradie, Norbert Ndjeka, Anna Marie Celina Garfin, Nino Lomtadze, Zaza Avaliani, Nana Kiria, Shelly Malhotra, Sarah Cook-Scalise, Sandeep Juneja, Daniel Everitt, Melvin Spigelman & Anna Vassall. (2021) Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ Open 11:12, pages e051521.
Crossref
Jacqueline P. Ernest, Jansy Sarathy, Ning Wang, Firat Kaya, Matthew D. Zimmerman, Natasha Strydom, Han Wang, Min Xie, Martin Gengenbacher, Laura E. Via, Clifton E. BarryIIIIII, Claire L. Carter, Radojka M. Savic & Véronique Dartois. (2021) Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy 65:10.
Crossref
N. Yu. Nikolenko, D. А. Kudlay & N. P. Doktorova. (2021) Pharmacoepidemiology and pharmacoeconomics of multidrug- and extensively drug-resistant tuberculosis. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 14:2, pages 235-248.
Crossref
Saeed Khoshnood, Mehdi Goudarzi, Elahe Taki, Atieh Darbandi, Ebrahim Kouhsari, Mohsen Heidary, Moloudsadat Motahar, Melika Moradi & Hadi Bazyar. (2021) Bedaquiline: Current status and future perspectives. Journal of Global Antimicrobial Resistance 25, pages 48-59.
Crossref
Gilbert Lazarus, Kevin Tjoa, Anthony William Brian Iskandar, Melva Louisa, Evans L. Sagwa, Nesri Padayatchi & Vivian Soetikno. (2021) The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis. PLOS ONE 16:3, pages e0248017.
Crossref
Oluwatoyin A. Adeleke, Logan Fisher, Ian N. Moore, Glenn A. Nardone & Alan Sher. (2020) A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model. ACS Pharmacology & Translational Science 4:1, pages 276-287.
Crossref
T. I. Armina Padmasawitri, Sarah Maria Saragih, Gerardus W. Frederix, Olaf Klungel & Anke M. Hövels. (2019) Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review. PharmacoEconomics - Open 4:2, pages 223-233.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.